X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ATA3219 is an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell monotherapy, e=which is being evaluated for the treatment of Lupus Nephritis.
Lead Product(s): ATA3219
Therapeutic Area: Nephrology Product Name: ATA3219
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
ATA3219 is an allogeneic CAR T-cell therapy targeting CD19+ B Cells, consists of allogeneic EBV T cells. It is being evaluated for the treatment of systemic lupus erythematosus with kidney involvement.
Lead Product(s): ATA3219
Therapeutic Area: Immunology Product Name: ATA3219
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
ATA188 (Allogeneic EBV T-cell), Atara’s investigational off-the-shelf T-cell candidate, has the potential to target EBV-infected B cells and plasma cells in the central nervous system that may catalyze autoimmune responses and MS pathophysiology.
Lead Product(s): ATA188
Therapeutic Area: Neurology Product Name: ATA188
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2023
Details:
Under the terms of the agreement, Pierre Fabre gains U.S. and remaining global commercial markets for tab-cel (tabelecleucel), an allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy.
Lead Product(s): Tabelecleucel
Therapeutic Area: Infections and Infectious Diseases Product Name: Tab-cel
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Pierre Fabre
Deal Size: $640.0 million Upfront Cash: $30.0 million
Deal Type: Partnership November 01, 2023
Details:
tab-cel (tabelecleucel) is an allogeneic, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells in an HLA-restricted manner.
Lead Product(s): Tabelecleucel
Therapeutic Area: Infections and Infectious Diseases Product Name: tab-cel
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Ebvallo™ (tabelecleucel) is an allogeneic, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells in an HLA-restricted manner.
Lead Product(s): Tabelecleucel
Therapeutic Area: Infections and Infectious Diseases Product Name: Ebvallo
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: Pierre Fabre
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
Ebvallo (tabelecleucel) is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease who have received at least one prior therapy.
Lead Product(s): Tabelecleucel
Therapeutic Area: Immunology Product Name: Ebvallo
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: HealthCare Royalty
Deal Size: $31.0 million Upfront Cash: $31.0 million
Deal Type: Agreement December 20, 2022
Details:
Ebvallo™ (tabelecleucel) as a monotherapy for the treatment of adult and pediatric patients two years of age and older with relapsed or refractory Epstein‑Barr virus positive post‑transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy.
Lead Product(s): Tabelecleucel
Therapeutic Area: Immunology Product Name: Ebvallo
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
ATA188 (Allogeneic EBV T-cell), Atara’s investigational off-the-shelf, allogeneic T-cell immunotherapy aims to specifically target EBV-infected B cells and plasma cells for progressive forms of multiple sclerosis (MS).
Lead Product(s): Allogeneic EBV T-cell
Therapeutic Area: Neurology Product Name: ATA188
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
Ebvallo (tabelecleucel) is an allogeneic, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells in an HLA-restricted manner.
Lead Product(s): Tabelecleucel
Therapeutic Area: Infections and Infectious Diseases Product Name: Ebvallo
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
